Atracurium Besylate
Who holds supplier records for Atracurium Besylate? 6 organisations hold a current record for Atracurium Besylate: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 5 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (2), Spain (1), Netherlands (1) and Latvia (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Atracurium Besylate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/atracurium-besylate
Reading the evidence
- 6 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (6)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Atracurium Besylate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- GLAND PHARMA LTDIndiaCEP Company GMP cert on recordActive DMF 21189, 29636 · latest filing Aug 2015
- FARMHISPANIA SASpainCEPActive DMF 11607 · latest filing Jul 1995
- TAPI NL BVNetherlandsCEPActive DMF 11742 · latest filing Nov 1995
- SOLARA ACTIVE PHARMA SCIENCES LTDIndia Company GMP cert on recordActive DMF 38238 · latest filing Mar 2023
- CF PHARMA LTDCEPInactive DMF 18444 · latest filing Jun 2005
- LatviaCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (5)
Certificates of Suitability on the EDQM register for Atracurium Besylate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 7 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| Grindeks AS Riga | LV | CEP 2024-519 - Rev 00 Atracurium besilate | Jun 2026 | Inspected Mar 2026 Latvia |
| CF PHARMA LTD. Budapest | HU | CEP 2020-436 - Rev 03 Atracurium besilate, Manufacturing code: 55 | Dec 2025 | Inspected Jan 2026 Hungary |
| TAPI NL B.V. Amsterdam | NL | CEP 2006-044 - Rev 07 Atracurium besilate | Jun 2025 | — |
| GLAND PHARMA LIMITED Hyderabad | IN | CEP 2008-272 - Rev 01 Atracurium besilate | Nov 2024 | Inspected Oct 2025 Germany |
| Farmhispania, S.A. Montmeló | ES | R1-CEP 2006-155 - Rev 00 Atracurium besilate | Jan 2013 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (2)
Organisations whose Type II DMFs for Atracurium Besylate are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- QUIMICA ESTEROIDAL SA DE CVInactive DMF 12120 · filed Sept 1996
- USA · Inactive DMF 11144 · filed Oct 1994
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Atracurium Besylate is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1200527).
Chemical identity
- IUPAC name
- benzenesulfonate;5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
- Canonical SMILES
- C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-]
- InChIKey
- XXZSQOVSEBAPGS-UHFFFAOYSA-L
- Synonyms
- Atracurium besilate, Atracurium besylate, Atracurium besylate preservative free, Atracurium dibesylate, Besilate d'atracurium, Besilato de atracurio, BW 33A, BW-33A, NSC-760047, Tracrium, Tracrium preservative free, WELLCOME 33-A-74
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Nondepolarizing Neuromuscular Blocker
- Physiologic effect
- Neuromuscular Nondepolarizing Blockade
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Atracurium Besylate?
6 organisations hold an active US FDA Type II Drug Master File or a CEP for Atracurium Besylate: GLAND PHARMA LTD (India), FARMHISPANIA SA (Spain), TAPI NL BV (Netherlands), SOLARA ACTIVE PHARMA SCIENCES LTD (India), CF PHARMA LTD and Grindeks (Latvia). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Atracurium Besylate Drug Master Files are active?
GLAND PHARMA LTD (DMF 21189, 29636), FARMHISPANIA SA (DMF 11607), TAPI NL BV (DMF 11742) and SOLARA ACTIVE PHARMA SCIENCES LTD (DMF 38238). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Atracurium Besylate records mean?
2 organisations have only inactive Type II DMFs for Atracurium Besylate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Atracurium Besylate have a European Certificate of Suitability?
Yes. 5 organisations hold a valid CEP for Atracurium Besylate on the EDQM register, including Grindeks AS Riga (LV), CF PHARMA LTD. Budapest (HU), TAPI NL B.V. Amsterdam (NL), GLAND PHARMA LIMITED Hyderabad (IN) and Farmhispania, S.A. Montmeló (ES). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Atracurium Besylate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Atracurium Besylate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.